AmyDTierstenMD

Associate Professor, Medicine, New York University School of Medicine

Overview of Dr. Tiersten

Dr. Amy Tiersten is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital and NYU Langone Hospitals. She received her medical degree from New York University Grossman School of Medicine and has been in practice 27 years. Dr. Tiersten accepts several types of health insurance, listed below. She is one of 145 doctors at NYU Langone Hospitals and one of 182 doctors at The Mount Sinai Hospital who specialize in Oncology. She has more than 70 publications and over 500 citings.

Office
1176 5th Ave
New York, NY 10029
Book by Phone+1(805) 585-5766

Fax+1 646-537-8610

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1990 - 1993
New York University School of MedicineClass of 1990

Certifications & Licensure

NY State Medical License 1991 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1997 Jan 01
Unknown status
Phase 1, Phase 2
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix Start of enrollment: 1997 Jan 01
Completed
Phase 2
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer Start of enrollment: 1997 Feb 01
Unknown status
Phase 2
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1998 May 01
Unknown status
Phase 2
S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 2
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2003 Apr 01
Terminated
Phase 2
Oxaliplatin and Topotecan in Advance Ovarian Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 2
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 1
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
RAD001 Plus Carboplatin in Breast Cancer Patients Start of enrollment: 2010 Jun 01
Completed
Phase 2
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
COMPLETED
PHASE3
Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy Start of enrollment: 2014 Sep 01
Completed
Not Applicable
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
ACTIVE_NOT_RECRUITING
PHASE3
Comparison of Single-Agent Carboplatin Vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer Start of enrollment: 2015 Dec 16
COMPLETED
PHASE2
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
COMPLETED
PHASE2
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Start of enrollment: 2016 Oct 01
Terminated
Phase 1
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Start of enrollment: 2017 Dec 20
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Start of enrollment: 2018 May 17
Completed
Phase 1
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer Start of enrollment: 2020 Oct 01
Withdrawn
Phase 2
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer Start of enrollment: 2024 Oct 28
RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation Start of enrollment: 2023 Oct 31
RECRUITING
PHASE3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience.
Rima Patel, Cao Jin, Diana Jaber, Nicole Casasanta, Mayuri Jain
Clinical Breast Cancer. 2025-04-01
PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting.
Mansi Saxena, Thomas U Marron, Julia Kodysh, John P Finnigan, Sayali Onkar
Cancer Discovery. 2025-03-17
Impact of race/ethnicity on MammaPrint genomic assay risk and prognosis in early breast cancer: A National Cancer Data Base analysis.
Rima B Patel, Tianxiang Sheng, Marcio A Diniz, Joseph A Sparano, Amy Tiersten
Cancer. 2025-03-01

Press Mentions

Breast Cancer Treatments Propel Many Women into ‘Rapid, Dramatic’ Medical MenopauseOctober 22nd, 2021
PARP Inhibitor Staves off Recurrence in Early BRCA-Mutant Breast CancerJune 16th, 2021
Lynparza Can Cure Breast Cancer at an Early StageJune 7th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment